Amgen (AMGN) Sales Grew 10%, but Can Earnings Catch Up to the Price?
Amgen (NASDAQ:AMGN) and AstraZeneca reported Phase 3 results this week for Tezspire in eosinophilic esophagitis, a condition that makes swallowing difficult.
Amgen Inc (AMGN)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bailard Inc Thomas Bailard | 49,176 | $20,728,504 | -1% | 0.42% |
| 2. | Lee Munder Capital Group Lee Munder | 37,026 | $15,606,992 | +4% | 0.84% |
| 3. | Zevenbergen Capital Investments Nancy Zevenbergen | 10,462 | $4,409,744 | +5% | 0.1% |
| 4. | Bourgeon Capital John Zaro | 3,404 | $1,434,821 | +1% | 0.21% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $165.50 | 10 | $1,655.00 | 3,582 | 2015-08-19 | Filing | |
| $166.64 | 3,000 | $499,907.10 | 3,572 | 2015-08-19 | Filing | |
| $152.29 | 1,500 | $228,435.00 | 2,000 | 2015-02-05 | Filing | |
| $152.29 | 1,500 | $228,435.00 | 2,000 | 2015-02-05 | Filing | |
| $111.77 | 894 | $99,919.25 | 185,013 | 2014-05-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $416.43 | 1,252 | $521,364.85 | 6,404 | 2026-08-13 | Filing | |
| $412.57 | 2,000 | $825,134.00 | 6,404 | 2026-08-11 | Filing | |
| $402.54 | 1,821 | $733,033.35 | 12,462 | 2026-08-06 | Filing | |
| $402.54 | 2,069 | $832,864.36 | 12,462 | 2026-08-06 | Filing | |
| $402.16 | 1,000 | $402,160.10 | 7,340 | 2026-08-06 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,080,066 | $455,258,620 | 0.44% | |
| 2. | 675,485 | $284,723,682 | 0.34% | |
| 3. | 586,504 | $247,217,281 | 5.25% | |
| 4. | 347,857 | $146,625,173 | 1.9% | |
| 5. | 324,455 | $136,761,027 | 0.93% |
News See All
Amgen Has the Drugs and the Dividend. Now It Needs the Growth
Amgen Inc. (NASDAQ:AMGN) has carved out a strong spot in the biotech world, thanks to its lineup of medicines for cancer, heart disease, inflammation, and some rare conditions.
Top 10 Unstoppable Dividend Stocks to Buy
Dividend cuts have been a major concern for income investors. It is easy to see why they dislike dividend reductions, suspensions, and eliminations.
10 No-Brainer Stocks to Buy Now
Fed Chair Kevin Warsh gave no hint of another rate hike at an IMF event in Bangkok on October 16, and the odds of an October increase fell to roughly 15% on CME FedWatch, according to Benzinga on October...
Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?
Biogen Inc. (NASDAQ:BIIB) closed at $225.71 on October 9.
Amgen (AMGN) and Johnson & Johnson (JNJ) Catch Jim Cramer’s Eye for Different Reasons
During the October 1 episode of Mad Money, Jim Cramer discussed Amgen Inc. (NASDAQ:AMGN) while reviewing the Dow Jones Industrial Average’s third-quarter performance.
Eli Lilly (LLY) and AbbVie (ABBV) Are Expanding Their Pipelines. Their Valuations Tell Two Different Stories
Obesity drugs, pipeline investment, and manufacturing capacity are reshaping the pharmaceutical industry's growth equation.
Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth?
On September 22, Amgen Inc. (NASDAQ:AMGN) announced positive topline Phase 3 results for dazodalibep in systemic Sjögren’s disease.
Can Roche’s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?
Roche's push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing...
Why Amgen’s Pipeline Just Got More Interesting
Amgen Inc. (NASDAQ:AMGN)'s experimental drug dazodalibep met the main goal of a late-stage trial for Sjögren’s disease.
Hedge Fund Resource Center